Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

Eucommia ulmoides Prevents Articular Cartilage Destruction via FPR2-LXA4 in the Rat Monoiodoacetate Model of Osteoarthritis

Doo ri Park, Chang hwan Yeo, Jee Eun Yoon, Wan-Jin Jeon, Woo-Jae Choung, In-Hyuk Ha*

Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, 06110, Seoul, South Korea

Abstract: Osteoarthritis (OA) is a debilitating joint disorder with high incidence. Therapies for OA are currently lacking due to limited understanding of its pathogenesis. Eucommia ulmoides (EU) is a traditional herbal medicine used to treat OA, but the mechanisms underlying its disease-controlling effects are poorly understood. This study reports the anti-OA effects of an EU extract as well as underlying mechanisms in a rat model of OA. In rats, EU diminished articular cartilage destruction. Furthermore, MMP3, MMP13, and FPR2 levels were decreased in the rat articular cartilage and primary chondrocytes treated with EU extract. Moreover, EU treatment regulated the levels of inflammatory cytokines, prostaglandin E₂ (PGE₂), and lipoxin A₄ (LXA₄) in intra-articular lavage fluid. These results demonstrate that EU inhibits the progression of OA by suppressing the FPR2-LXA₄ pathway to reduce inflammatory cytokines levels and block cartilage degeneration. Therefore, EU is a potential therapeutic agent for OA.

Keywords: Eucommia ulmoides, cartilage, chondrocytes, inflammation, osteoarthritis

Received March 13, 2022; Revised April 17, 2022; Accepted April 26, 2022

Citation: Doo ri Park, Chang hwan Yeo, Jee Eun Yoon, Wan-Jin Jeon, Woo-Jae Choung, In-Hyuk Ha, Eucommia ulmoides Prevents Articular Cartilage Destruction via FPR2-LXA4 in the Rat Monoiodoacetate Model of Osteoarthritis. Journal of Food and Nutrition Research, 10 (4). 313-320. January 2022. doi:10.12691/jfnr-10-4-8

1. Introduction

Osteoarthritis (OA) is the most common degenerative joint disease, causing pain mainly in the weight-supporting joints, such as the knees, and is associated with many identified risk factors (for example, mechanical stress, metabolic or genetic factors) [1,2,3]. OA is characterized by articular cartilage degeneration, and synovial inflammation [4,5]. A variety of latent OA-causing mechanisms have been included as biochemical factors, such as pro-inflammatory cytokines, which reduce the ability of chondrocytes to produce extracellular matrix and disrupt extracellular matrix molecules through catabolic matrix-degrading enzymes [6,7,8].

Previous studies have shown that inflammatory molecules, including cytokines and adipokines, can damage joints [9]. Increased joint inflammation through synovitis in the joint cavity plays an important role in the pathology of OA [10,11]. Thus, studies on inflammation are an effective approach to understand the pathological response of OA, whereas the inflammation that occurs in OA is not serious. Regarding low-grade inflammation, the role of adipokines produced in adipose tissue and released into the blood has been widely studied in recent years [12]. The lipid mediator lipoxin A₄ (LXA₄) is an endogenous bioactive product of arachidonic acid that has been reported to regulate a variety of effects in multiple tissues, including anti-inflammation, neutrophil infiltration, and macrophage polarization, and its therapeutic effect on OA has been confirmed by previous studies [13,14,15,16,17]. LXA₄ is formed by activation of the oxylipin pathway in the fat pad below the articular cartilage and the action of 12-lipoxygenase in the capillaries [14,18]. These activities of LXA₄ are regulated by the G protein-coupled FPR2/ALX receptor, and recent studies have shown that FPR2 is expressed in human articular chondrocytes [19,20,21]. LXA₄ exerts antagonistic effects via FPR2/ALX, as it induces the accumulation of presqualene diphosphate, leading to the inhibition of NF-κB activation during the inflammatory response [22]. NF-κB signaling plays a central role in regulating the inflammatory response during OA pathogenesis [23].

Eucommia ulmoides Oliver Bark (EU), also known as Eucommiae Cortex or Du Zhung, has been traditionally used in oriental medicine for its antiviral, antihypertensive, anti-inflammatory, and renal- and hepatoprotective effects (without side effects) [24,25,26,27]. In addition, it strengthens muscles and lungs, lowers blood pressure, prevents miscarriage, and strengthens tendons and bones. EU prevents OA by protecting cartilage through improved metabolism and the inhibition of extracellular matrix breakdown [28]. Therefore, EU is the main herbal ingredient used in “Jaseng SHINBARO,” which has been used clinically for the treatment of arthritis, discs, and ankylosing spondylitis and was approved as a New Herbal Medicine for the treatment of osteoarthritis by the Korean FDA in 2011 [29]. SHINBARO is a purified extract from a mixture of six oriental herbs (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, and Eucommiae Cortex). Studies have shown that SHINBARO reduces inflammation and cartilage degradation as a primary herbal prescription for degenerative arthritis [30]. According to a recent study, EU extract was found to affect OA by inhibiting inflammatory mediators, but the precise mechanism is still not known. Therefore, we investigated the effects of EU extract on inflammation-mediated signaling in a rat model of OA, as well as the potential mechanisms.

2. Materials and Methods

2.1. Preparation of Extract from EU

EU was purchased from Green M.P. Pharm. Co., Ltd (Gyeonggido, Korea). The aqueous extract of EU was prepared with distilled water, then heated to boiling using the reflux apparatus at 105°C for 3 h, and filtered with filter paper at 20-22°C. The filtrate was cooled at −20°C and lyophilized with a freeze dryer (Ilshin BioBase Co., Ltd, Gyeonggido, Korea) to obtain EU dry extract, which was then stored at −20°C until use.

2.2. Experimental OA in Rats

Sprague-Dawley (SD) male rats were used for experimental OA studies. We purchased 5–6-week-old SD male rats from Orient Bio (Seongnam, Korea). Experimental OA was induced via the intra-articular (IA) injection of monoiodoacetate (MIA; 2 mg dissolved in 30 μl of phosphate-buffered saline) at the right knee joint space through the suprapatellar ligament [31]. The MIA was purchased from Sigma-Aldrich (St Louis, MO, USA). To assess the recovery of articular cartilage from OA induction, the oral administration of EU extract dissolved in distilled water (50, 100, and 250 mg/kg body weight) was performed daily for 4 weeks, beginning 1 week after IA injection. Rats were euthanized at 5 weeks after IA injection and subjected to biochemical and histological analyses. All rats were maintained in separate cages with a constant temperature (23–25°C) and humidity (45–50%) and a 12 h light/dark cycle. The rats had free access to food and water. All animal experiments were approved by the Institutional Animal Care and Use Committees (IACUC) (Protocol No: JSR-2019-09-001-001) of Jaseng Spine and Joint Research Institute and conformed with the allowed National Research Council Guidelines.

2.3. Behavioral Test (Von Frey Withdrawal Threshold)

Mechanical allodynia was measured using a dynamic plantar series (Plantar Test, Ugo Basile, Italy). The rat was first acclimated to a wire mesh cage (28 28 10 cm). Once the rat had acclimatized to the apparatus and ceased exploratory behavior, the operator placed the touch simulator below the rat’s paw. The unit then automatically raised the filament at a preset force until a signal was received that the rat had either moved its paw or the greatest preset force had been met for 20 min. Measurements were carried out for 4 weeks, were performed at intervals to reduce sensitization, and were repeated five times per measurement. Pain behavior was assessed as mechanical hyperalgesia, measured with a dynamic plantar esthesiometer, and was quantified as paw withdrawal latency.

2.4. Micro-CT Analysis

To analyze the degree of OA, knee joints were isolated from rats at the end of experiments. The knee joints were fixed in 10% formaldehyde and scanned using a Viva CT 80 in vivo μCT scanner (Scanco Medical AG, Brüttisellen, Switzerland) at 55 kV and 72 μA. Total 360° views were acquired at 0.7° angle increments, each for an exposure time of 400 ms, to give a resolution of 32 mm. From the acquired two-dimensional images, structural parameters of the femur and tibial trabecular bone were evaluated with a μCT Evaluation Program V6.6 (Scanco Medical AG, Brüttisellen, Switzerland), including the BMD (mm³), BV/TV (%), and Tb.Th (1/μm).

2.5. Histology and Immunohistochemistry

At the end of the experiments, the knee joints were fixed with 10% formaldehyde over 48 h at 4°C, decalcified in 0.5 M EDTA in phosphate-buffered saline (PH 7.4) for 2 weeks, and embedded in paraffin. Next, the paraffin blocks were cut into 5-μm sections and stained with safranin-O and fast green. Cartilage destruction was scored by the OARSI scores method (grade 0–6), a standard OA-grading system [32]. Cartilage destruction were identified by safranin-O staining and measured using NIS-Elements BR 5.01 software (Nikon Instruments Inc., Seoul, Korea) with an Eclipse Ti2 (Nikon). Immunostaining was conducted using a standard protocol. Sectioned knee joints were incubated with a primary antibody against FPRL1/FPR2 (NLS1878; Novus Biologicals, LLC, CO, USA) overnight at 4 °C. For immunohistochemical staining, a DAB peroxidase substrate detection kit (Vector Laboratories, Inc, USA) was used to detect the immunoactivity, and knee joints were stained with hematoxylin by counter-staining. Additional immunostaining was performed using antibodies against MMP13 (ab53015; Abcam) and COL2A1 (SC 52658; Santa Cruz Biotechnology).

2.6. Enzyme-linked Immunosorbent Assays (ELISAs)

To determine the level of LXA₄, the knee IALF was collected at the end of the experiments and assessed using a commercial quantitative ELISA kit (MBS755644, MyBioSource, CA, USA) according to the manufacturer’s instructions. Commercial quantitative ELISA kits were as follows: TNF-α (558535, BD Biosciences Pharmingen, CA, USA), IL-6 (550319, BD Biosciences Pharmingen), IL-1β (DY501, R & D Systems Inc., MN, USA), PGE2 (ab133021, Abcam), and CTXII (NBP2-75851, Novus Biologicals).

2.7. Primary Culture of Articular Chondrocytes

Rat articular chondrocytes were isolated from femoral condyles and tibial plateaus of 3–4-day-old rats by digestion with 0.2% collagenase type II [33]. The cells were maintained in Dulbecco’s modified Eagle’s medium (HyClone, Logan, UT, USA) containing 10% fetal bovine serum. Cells were treated with EU at various doses and treated with IL-1β (10 ng/ml) for 24 h.

2.8. RNA Isolation and Real-time PCR

Total RNA was isolated from primary chondrocytes using TRIzol reagent (Life Technologies, Carlsbad, CA, USA) or knee joint tissues using a RNeasy Mini Kit (Qiagen, Hilden, Germany). It was then reverse transcribed to complementary DNA using AccuPower RT PreMix (Bioneer, Daejeon, Korea) following the manufacturer’s instructions. Real-time PCR analysis was performed using SYBR green supermix (Bio-Rad, Hercules, CA) on an iCycler iQ Real-Time PCR Detection System (Bio-Rad). Samples were analyzed in triplicate and normalized to β-actin mRNA expression. Primer sequences are listed in Table 1.

Table 1. PCR primers

2.9. Western Blotting and Immunoprecipitation

Chondrocytes were extracted with RIPA lysis buffer (Biosesang, Sungnam, Korea) containing protease and phosphatase inhibitors. The following antibodies were used for western blotting: anti-Col2a1 from Santa Cruz, anti-MMP3 and anti-MMP13 from Abcam, and anti-IL-1β and anti-FPR2 from Novus Biologicals. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnologies, Santa Cruz, CA) and β-actin (Santa Cruz) antibodies were used as loading controls.

2.10. Statistics

All data are expressed as the means ± SDs from at least three independent experiments. Statistical analyses were performed using one-way analysis of variance to analyze differences between groups. Dunnett’s multiple comparisons tests were performed to determine significant differences among the groups. P values less than 0.05 were considered statistically significant.

3. Results

3.1. EU Reduces Cartilage Degradation

To elucidate the effect of EU extract in OA pathogenesis, we examined a rat model of OA induced by MIA injection. EU extract slightly mitigated the weight loss due to MIA-induced OA and resulted in a behavioral recovery effect based on the Von Frey observation experiment. Moreover, histological analysis revealed that EU extract resulted in gradually less cartilage destruction in a dose-dependent manner, as determined by Osteoarthritis Research Society International (OARSI) scoring with safranin-O staining (Figure 1).

Figure 1. Effects of Eucommia ulmoides (EU) on monoiodoacetate (MIA)-induced osteoarthritis (OA) in rats. (A) Pain behavior was assessed as mechanical hyperalgesia, measured with a dynamic plantar esthesiometer, and was quantified as paw withdrawal latency (right) (n = 10 per group). (B, C) Experimental OA was examined by scoring of OA parameters, including articular cartilage destruction (OARSI grade) (B) and safranin-O staining (C) (n = 10). Scale bar = 200 μm. Values are expressed as the mean ± SEM. One-way ANOVA was performed followed by Dunnett’s multiple comparisons test. OARSI, Osteoarthritis Research Society International. Pound keys (#) indicate statistical significance (###P < 0.005) relative to Sham operated group. Asterisks (*) indicate statistical significance (**P < 0.05, ***P < 0.005) comparing EU-treated groups relative to MIA injected group.

3.2. EU Reduces Cartilage Degradation

To assess morphological changes in the knee articular bone, the right femur and tibia of rats were analyzed by micro-CT. The EU extract not only suppressed cartilage destruction but also recovered the reduction of bone mineral density (BMD), bone volume/total volume (BV/TV), and trabecular thickness (Tb.Th) due to MIA. These results suggested that EU extract affects OA pathogenesis in rats (Figure 2).

Figure 2. Eucommia ulmoides (EU) improves trabecular bone. Representative 3D reconstructed micro-CT images (A) and quantitative analysis (B) of rat tibia bone at 4 weeks post monoiodoacetate (MIA)-injection compared with to those in the sham control (n = 4). Scale bars = 1,000μm. Values are expressed as the mean ± SEM. One-way ANOVA was performed followed by Dunnett’s multiple comparisons test. BMD, bone mineral density; BV/TV, bone volume/total volume; Tb.Th, trabecular thickness.Pound keys (#) indicate statistical significance (###P < 0.005) relative to Sham operated group. Asterisks (*) indicate statistical significance (*P < 0.05, ***P < 0.005) comparing EU-treated groups relative to MIA injected group

3.3. EU Inhibits FPR2-induced Inflammatory OA Pathogenesis

To determine the mechanism underlying the effect of the EU extract, the mRNA of articular cartilage tissue was analyzed by qRT-PCR analysis. Therefore, EU extract was found to regulate OA markers such as Mmp3, Mmp13, and Col2a1. In addition, EU decreased the expression of Fpr2, the LXA4 receptor, which was increased in the MIA-induced OA group. Moreover, immunohistochemical-analysis revealed that the EU extract regulated OA-related proteins including MMP13, COL2A1, and FPR2 (Figure 3).

Figure 3. Eucommia ulmoides (EU) inhibits osteoarthritis (OA) pathogenesis. (A, B) qRT-PCR analysis of rat cartilage tissues. The mRNA levels of Mmp3, Mmp13, Col2a1 (A), and Fpr2 (B) were determined by real-time PCR, and the values were normalized to β-actin expression. (C-E) Immunohistochemical analyses of MMP13 (C), COL2A1 (D), and FPR2 (E) in OA articular cartilage from monoiodoacetate (MIA)-injected rats compared with those in sham-operated rats (n = 4). Scale bars = 100 μm. Values are expressed as the mean ± SEM. One-way ANOVA was performed followed by Dunnett’s multiple comparisons test. MMP3, Matrix Metallopeptidase 3; MMP13, Matrix Metallopeptidase 13; COL2A1, Collagen Type II Alpha 1 Chain; FPR2, Formyl Peptide Receptor 2. Pound keys (#) indicate statistical significance (#P < 0.05, ##P < 0.05, ###P < 0.005) relative to Sham operated group. Asterisks (*) indicate statistical significance (*P < 0.05, **P < 0.05, ***P < 0.005) comparing EU-treated groups relative to MIA injected group

3.4. EU reduces OA Signaling in Rat Articular Chondrocytes

FPR2, the receptor for LXA₄, is endogenously expressed in articular cartilage which regulates NF-κB activation in inflammatory response [22]. To confirmed the inhibitory effects of EU extract on rat articular chondrocytes, these cells were incubated with multiple doses of EU extract for 24 h with IL-1β (10 ng/ml)-treated media. We found that EU extract regulated all OA-induced markers, including Mmp3, Mmp13, and Col2A1, by qRT-PCR analysis. EU extract also inhibited the expression of IL-1β, encoding an inflammatory cytokine, and Fpr2 in rat articular chondrocytes. These results were confirmed through western blot analysis (Figure 4).

Figure 4. Effects of Eucommia ulmoides (EU) on rat articular chondrocytes. Rat articular chondrocytes were either not treated or treated with EU extract (0.5, 5, 50 μg/ml) and exposed to IL-1β(10 ng/ml) for 24 h. (A-D) The mRNA levels of Mmp3, Mmp13, Col2a1 (A), IL-1β (B), and Fpr2 (C) were detected by qRT-PCR, whereas proteins were assessed by western blot analysis (D). Values are expressed as the mean ± SEM. One-way ANOVA was performed followed by Dunnett’s multiple comparisons test. MMP3, Matrix Metallopeptidase 3; MMP13, Matrix Metallopeptidase 13; COL2A1, Collagen Type II Alpha 1 Chain; FPR2, Formyl Peptide Receptor 2; IL-1βInterleukin-1beta. Pound keys (#) indicate statistical significance (###P < 0.005) relative to none treated cells. Asterisks (*) indicate statistical significance (**P < 0.05, ***P < 0.005) comparing EU extract-treated cells relative to IL-1β treated cells.

3.5. EU Regulates OA Pathogenesis via the Inflammatory Response in Rats with MIA-induced OA

To investigate the inhibition of osteoarthritis through FPR2, we measured intra-articular lavage fluid (IALF) in the joint cavity. The levels of TNF-α, IL-6, and IL-1β significantly increased in the MIA-injected group, and that of these inflammatory cytokines was reduced in the EU extract-treated group. Moreover, level of PGE2, a pain marker, was attenuated in the EU extract (250 mg/kg)-treated group. CTXII is a fragment of collagen that increases in the IALF when cartilage is destroyed by OA. The level of CTXII was decreased in the EU groups. LXA₄ binds to FPR2 and regulates inflammation caused by OA [15]. Under normal conditions, LXA₄ is present in the IALF of the joint cavity; however, when OA is triggered, it becomes attached to FPR2, a receptor present in the cartilage, and its concentration in the IALF decreases [15,16,17,34]. In the MIA group, the level of LXA₄ was reduced compared with that in the sham group, whereas it was increased in the EU extract (250 mg/kg)-treated group. Our study suggests that EU extract suppresses the inflammatory response of OA and reduces pain through FPR2-LXA₄, which inhibits OA markers such as MMP3 and MMP13 and prevents the suppression of COl2A1, helping to prevent and treat OA (Figure 5).

Figure 5. Eucommia ulmoides (EU) regulates LXA₄ and inflammatory responses induced by monoiodoacetate (MIA). (A-D) Levels of TNF-α, IL-6, IL-1β (A), PGE2 (B), CTXII (C), and LXA₄ (D) in intra-articular lavage fluid (IALF) were determined by enzyme-linked immunosorbent assay. Values are expressed as the mean ± SEM. One-way ANOVA was performed followed by Dunnett’s multiple comparisons test. LXA4, Lipoxin A₄; TNF-α, tumor necrosis factor-alpha; IL-6, Interleukin-16; IL-1βInterleukin-1beta; PGE2, Prostaglandin E2; CTXII, C-telopeptide fragments of type II collagen.Pound keys (#) indicate statistical significance (#P < 0.05, ###P < 0.005) relative to Sham operated group. Asterisks (*) indicate statistical significance (*P < 0.05, **P < 0.05, ***P < 0.005) comparing EU-treated groups relative to MIA injected group

4. Discussion

Degenerative diseases are on the rise as the elderly population increases worldwide. OA is a common degenerative disease, and its prevalence is steadily increasing. OA is a general degenerative arthritis that affects the joints of the knee, hip, lumbar region, shoulder, hand, and foot, in which joint cartilage is destroyed and becomes thinner [2,35]. People with OA suffer from movement limitations and pain. There are no OA therapeutic drugs, and only non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors are used to reduce inflammation and pain. However, many of these pain relievers have side effects, such as gastrointestinal problems, and the best way to treat OA is joint replacement surgery [36,37]. Therefore, many researchers are looking for new therapeutics to reduce side effects, focusing on herbal extract that are generally more tolerable than synthetic medications [38,39]. OA is a debilitating disease affecting articular cartilage. Inflammation is closely related to all stages of OA progression, and the inflammatory factors TNF-α and IL-1β ultimately cause cartilage damage, increasing MMP3 and MMP13 and decreasing COL2A1 levels. The inflammatory response results in swelling of the tissues around the joints, associated with cartilage destruction [40,41,42,43,44].

EU extract is a herbal product traditionally known to be effective for bone and joint health, anti-inflammatory effects, and pain relief, with fewer side effects. Therefore, we studied the efficacy and mechanism of EU extract in OA. In this study, we found that EU extract showed inhibitory effects in the behavioral test to measure pain. In addition, EU extract reduced cartilage destruction and helped with the regeneration of bone based on micro-CT results. The levels of TNF-α, IL-6, and IL-1β in IALF were increased in OA-induced rats, but all decreased in a dose-dependent manner in EU extract-treated groups. PGE2 is a molecule that increases the sensitivity of neurons to pain. Like inflammatory cytokines, its expression was increased due to OA but was inhibited by the extract of EU, especially at 250 mg/kg. These results support the anti-inflammatory and analgesic effects of EU extract.

Type II collagen is primarily found in cartilage and is a major structural component [45]. Collagen type II content is decreased during OA development; therefore, the level of CTXII, a fragment of type II collagen, is increased in IALF. Increased CTXII level is a biomarker of early OA [46,47]. EU extract was also effective in early OA and functioned by decreasing the content of CTXII.

OA is usually associated with the early development of mild inflammation, rather than severe inflammation. [14,15,16,17] We, thus, assessed the level of LXA₄, aside from the commonly known TNF-α and IL-1β markers, to determine the effects of EU extract on early inflammation. Specifically, 250 mg/kg EU extract increased LXA₄ and showed an effective inhibitory effect on the initial inflammatory response.

LXA₄ exists endogenously in IALF, and when inflammation occurs, it binds to the cell membrane receptor FPR2/ALX, after which its level in synovial fluid decreases, whereas FPR2 level increases [20,22]. EU extract decreased the increased level of FPR2 in MIA-induced OA and specifically attenuated the expression of MMP3, MMP13, and COL2A1 in the 250 mg/kg treatment group. These results were also verified in rat primary articular chondrocytes. Our studies showed that EU extract inhibits OA by regulating the initial inflammatory response, but further studies on specific binding molecules and their sub-signals should be performed.

5. Conclusion

Our findings suggest that EU extract reduces OA pathogenesis by inhibiting early inflammation via LXA₄-FPR2. These results indicate that EU extract could be a potential therapeutic agent for OA treatment, with fewer side effects than conventional anti-inflammatory analgesics such as NSAIDs.

Acknowledgements

None.

Conflict of Interest

The authors declare that there are no conflict of interests.

References

[1]   | Hootman, J. M., Helmick, C. G., “Projections of US prevalence of arthritis and associated activity limitations,” Arthritis. Rheum., 54, 226-229, 2006.
[2]   | Goldring, M. B., Goldring, S. R., “Osteoarthritis,” J. Cell. Physiol., 213, 626-634, 2007.
[3]   | Loeser, R. F., “Molecular mechanisms of cartilage destruction: mechanics, inflammatory mediators and aging collide,” Arthritis. Rheum., 54, 1357-1360, 2006.
[4]   | Suri, S., Walsh, D. A., “Osteochondral alterations in osteoarthritis,” Bone, 51, 204-211, 2012.
[5]   | Zhang, X., Xu, X., Xu, T., Qin, S., “β-Ecdysterone suppresses interleukin-1β-induced apoptosis and inflammation in rat chondrocytes via inhibition of NF-κB signaling pathway,” Drug. Dev. Res., 75, 195-201, 2014.
[6]   | Latourte, A., Cherifi, C., Maillet, J., Ea, H., Bouaziz, W., Funck-Brentano, T., Cohen-Solal, M., Hay, E., Richette, P., “Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis,” Ann. Rheum. Dis., 76, 748-755, 2017.
[7]   | Loeser, R. F., Goldring, S. R., Scanzello, C. R., Goldring, M. B., “Osteoarthritis: a disease of the joint as an organ,” Arthritis. Rheum., 64, 1697-1707, 2012.
[8]   | Mobasheri, A., Rayman, M. P., Gualillo, O., Sellam, J., van der Kraan, P., Fearon, U., “The role of metabolism in the pathogenesis of osteoarthritis,” Nat. Rev. Rheumatol., 13, 302-311, 2017.
[9]   | Cicuttini, F. M., Wluka, A. E., “Not just loading and age: the dynamics of osteoarthritis, obesity and inflammation,” Med. J. Aust., 204, 47, 2016.
[10]   | Malfait, A. M., “Osteoarthritis year in review 2015: biology,” Osteoarthritis Cartilage, 24, 21-26, 2016.
[11]   | Liu-Bryan, R., “Inflammation and intracellular metabolism: new targets in OA,” Osteoarthritis Cartilage, 23, 1835-1842, 2015.
[12]   | Berenbaum, F., van den Berg, W. B., “Inflammation in osteoarthritis: changing views,” Osteoarthritis Cartilage, 23, 182-1824, 2015.
[13]   | Serhan, C. N., Chiang, N., “Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus,” Br. J. Pharmacol., 153, S200-S215, 2008.
[14]   | McMahon, B., Mitchell, S., Brady, H. R., Godson, C., “Lipoxins: revelations on resolution,” Trends. Pharmacol. Sci., 22, 391-395, 2001.
[15]   | Sodin-Semrl, S., Taddeo, B., Tseng, D., Varga, J., Fiore, S., “Lipoxin A4 inhibits IL-1β-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases,” J. Immunol., 164, 2660-2666, 2000.
[16]   | Chan, M. M., Moore, A. R., “Resolution of Inflammation in Murine Autoimmune Arthritis Is Disrupted by Cyclooxygenase-2 Inhibition and Restored by Prostaglandin E 2-Mediated Lipoxin A4 Production,” J. Immunol. 184, 6418-6426, 2010.
[17]   | Conte, F. P., Menezes-de-Lima, O. Jr., Verri, WA. Jr., Cunha, F. Q., Penido, C., Henriques, M. G., “Lipoxin A4 attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects,” Br. J. Pharmacol., 161, 911-924, 2010.

[18]  
Gierman, L. M., Wopereis, S., van El, B., Verheij, E. R., Werff-van der Vat, B. J. C., Bastiaan-sen-Jenniskens, Y. M., van Osch, G. J. V. M., Kloppenburg, M., Stojanovic-Susulic, V., Huizinga, T. W. J., et al., “Metabolic Profiling Reveals Differences in Concentrations of Oxylipins and Fatty Acids Secreted by the Infrapatellar Fat Pad of Donors With End-Stage Osteoarthritis and Normal Donors,” Arthritis. Rheum., 65, 2606-2614, 2013.

[19]   | Krishnamoorthy, S., Recchiuti, A., Chiang, N., Yacoubian, S., Lee, C. H., Yang, R., Petasis, N. A., Serhan, C. N., “Resolvin D1 binds human phagocytes with evidence for proresolbing receptors,” Proc. Natl. Acad. Sci. U. S. A., 107, 1660-1665, 2010.
[20]   | Brink, C., Dahlén, S., Drazen, J., Evans, J. F., Hay, D. W. P., Nicosia, S., Serhan, C. N., Shimizu, T., Yokomizo, T., “International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors,” Pharmacol. Rev., 55, 195-227, 2003.
[21]   | Holmertz, A. S., Jonsson, C. A., Mohaddes, M., Lundqvist, C., Forsman, H., Gjertsson, I., Önn-heim, K., “Data describing expression of formyl peptide receptor 2 in human articular chondrocytes,” Data. Brief., 31, 105866, 2020.
[22]   | József, L., Zouki, C., Petasis, N. A., Serhan, C. N., Filep, J. G., “Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-κB and AP-1 activation, and IL-8 gene expression in human leukocytes,” Proc. Natl. Acad. Sci. U. S. A., 99, 13266-13271, 2002.
[23]   | Marcu, K. B., Otero, M., Olivotto, E., Borzi, R. M., Goldring, M. B., “NF-κB signaling: multiple angles to target OA,” Curr. Drug. Targets., 11, 599-613, 2010.
[24]   | He, X., Wang, J., Li, M., Hao, D., Yang, Y., Zhang, C., He, R., Tao, R., “Eucommia ulmoides Oliv.: ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine,” J. Ethnopharmacol., 151, 78-92, 2014.
[25]   | Hsieh, C. L., Yen, G. C., “Antioxidant actions of du-zhong (Eucommia ulmoides Oliv.) toward oxidative damage in biomolecules,” Life. Sci., 66, 1387-1400, 2000.
[26]   | Kwan, C. Y., Chen, C., Deyama, T., Nishibe, S., “Endothelium-dependent vasorelaxant effects of the aqueous extracts of the Eucommia ulmoides Oliv. Leaf and bark: Implications on their antihypertensive action,” Vasc. Pharmacol., 40, 229-235, 2003.
[27]   | Zhao, Y., Li, Y., Wang, X., Sun, W., “The experimental study of Cortex Eucommiae on meridian tropsim: The distribution study of aucubin in rat tissues,” J. Pharm. Biomed. Anal., 46, 368-373, 2008.
[28]   | Lu, H., Jiang, J., Xie, G., Liu, W., Yan, G., “Effects of an aqueous extract of Eucommiae on articular cartilage in a rat model of osteoarthritis of the knee,” Exp. Ther. Med., 684-688, 2013.
[29]   | Lee, S., Kwon, H., Lee, S., “SHINBARO, a new herbal medicine with multifunctional mechanism for joint disease: First therapeutic application for the treatment of osteoarthriti,” Arch. Pharm. Res., 34, 73-1777, 2011.
[30]   | Kim, W. K., Chung, H., Pyee, Y., Choi, T. J., Park, H. J., Hong, J., Shin, J., Lee, J. H., Ha, I., Lee, S. K., “Effects of intra-articular SHINBARO treatment on monosodium iodoacetate-induced osteoarthritis in rats,” Chin. Med., 11, 17, 2016.

[31]  
Lee, S. W., Song, Y. S., Shin, S. H., Kim, K. T., Park, Y. C., Park, B. S., Yun, I., Kim, K., Lee, S. Y., Chung, W. T., et al., “Cilostazol protects rat chondrocytes against nitric oxide-induced apoptosis in vitro and prevents cartilage destruction in a rat model of osteoarthritis,” Arthritis. Rheum., 58, 790-800, 2008.

[32]   | Glasson, S. S., Chambers, M. G., Van Den Berg, W. B., Little, C. B., “The OARSI histopathology initiative–recommendations for histological assessments of osteoarthritis in the mouse,” Osteoarthritis Cartilage, 18, S17-S23, 2010.
[33]   | Gosset, M., Berenbaum, F., Thirion, S., Jacques, C., “Primary culture and phenotyping of murine chondrocytes,” Nat. Protoc., 3, 1253-1260, 2008.
[34]   | Yang, Y., Wang, Y., Kong, Y., Zhan, X., Bai, L., “The effects of different frequency treadmill exercise on lipoxin A4 and articular cartilage degeneration in an experimental model of monosodium iodoacetate-induced osteoarthritis in rats. Plos One, 12, e0179162, 2017.
[35]   | Felson, D. T., “Developments in the clinical understanding of osteoarthritis,” Arthitis. Res. Ther., 11, 203, 2009.
[36]   | Rannou, F., Pelletier, J. P., Martel-Pelletier, J., “Efficacy and safety of topical NSAIDs in the management of osteoarthritis: evidence from real-life setting trials and surveys,” Semin. Atrhtitis. Rheum., 45, S18-21, 2016.
[37]   | Brizuela, N. Y., Montrull, H. L., Demurtas, S. L., Meirovich, C. I., “Articular cartilage in osteoarthritic patients: effects of declofenac, celecoxib and glucosamine sulfate on inflammatory markers,” Rev. Fac. Cien. Med. Univ. Nac. Cordoba., 64, 9-15, 2007.
[38]   | Da Costa, B. R., Reichenbach, S., Keller, N., Nartey, L., Wandel, S., Jüni, P., Trelle, S., “Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: A network meta-analysis,” Lancet, 390, e21-e33, 2017.
[39]   | Izzo, A. A., Kim, S. H., Radhakrishnan, R., Williamson, E. M., “A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies,” Phytother. Res., 30, 691-700, 2016.
[40]   | Pfander, D., Heinz, N., Rothe, P., Carl, H., Swoboda, B., “Tenascin and aggrecan expression by articular chondrocytes is influenced by interleukin 1β: A possible explanation for the changes in matrix synthesis during osteoarthritis,” Ann. Rheum. Dis., 63, 240-244, 2004.
[41]   | Meulenbelt, I., Seymour, A. B., Nieuwland, M., Huizinga, T. W. J., van Duijin, C. M., Slagboom, P. E., “Association of the interleukin-1 gene cluster with radiographic signs of osteoarthritis of the hip,” Arthritis. Rheum., 50, 1179-1186, 2004.
[42]   | Sakkas, L. I., Johanson, N. A., Scanzello, C. R., Platsoucas, C. D., “Interleukin-12 is expressed by infiltrating macrophages and synovial lining cells in rheumatoid arthritis and osteoarthritis,” Cell. Immunol., 188, 105-110, 1998.

[43]  
Scanzello, C. R., Umoh, E., Pessler, F., Diaz-Torne, C., Dicarlo, E., Potter, H. G., Mandl, L., Marx, R., Rodeo, S., Goldring, S. R., et al., “Local cytokine profiles in knee osteoarthritis: Elevated synovial fluid interleukin-15 differentiates early from end-stage disease,” Osteoarthritis Cartilage, 17, 1040-1048, 2009.

[44]   | Campo, G. M., Avenoso, A., D’Ascola, A., Scuruchi, M., Prestipino, V., Calatroni, A., Campo, S., “Hyaluronan in part mediates IL-1β-induced inflammation in mouse chondrocytes by up-regulating CD44 receptors,” Gene, 494, 24-35, 2012.
[45]   | Prockop, D. J., Kivirikko, K. I., “Collagens: Molecular biology, diseases, and potentials for therapy,” Annu. Rev. Biochem., 64, 403-434, 1995.
[46]   | Chu, X. Q., Wang, J. J., Dou, L. D., Zhao, G., “Cartilage oligomeric matrix protein and matrix metalloproteinase-3 expression in the serum and joint fluid of a reversible osteoarthritis rabbit model,” Genet. Mol. Res., 14, 14207-14215, 2015.
[47]   | Jiao, Q., Wei, L., Chen, C., Li, P., Wang, X., Li, Y., Guo, L., Zhang, C., Wei, X., “Cartilage oligomeric matrix protein and hyaluronic acid are sensitive serum biomarkers for early cartilage lesions in the knee joint,” Biomarkers, 21, 146-151, 2016.